|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Cash flows from operating activities | |||||
| Net income (loss) - before noncontrolling interest (“NCI”) | |||||
| Adjustments to reconcile net income (loss) - before NCI to net cash used in operating activities | |||||
| Depreciation expense | |||||
| Depreciation and amortization expense | |||||
| Stock-based compensation | |||||
| Gain on sale of intellectual property | |||||
| Gain on deconsolidation of subsidiary | |||||
| Change in fair value - equity method investment | |||||
| APA-RDx: Issue common stock of subsidiary - termination payment | |||||
| Issue common stock - vendor service agreement | |||||
| Amortization of common stock payment for vendor service agreement | |||||
| Loss on issue - Senior Secured Convertible Note | |||||
| Issuance of stock for services | |||||
| Change in fair value - Senior Secured Convertible Notes | |||||
| Debt extinguishment loss - Senior Secured Convertible Note | |||||
| Non-cash lease expense | |||||
| Changes in operating assets and liabilities: | |||||
| Accounts receivable | |||||
| Prepaid expenses, deposits and current and other assets | |||||
| Accounts payable | |||||
| Accrued expenses and other current liabilities | |||||
| Net cash flows used in operating activities | |||||
| Cash flows from investing activities | |||||
| Purchase of equipment | |||||
| Proceeds from sale of intellectual property to Lucid Diagnostics Inc. | |||||
| Decrease in cash due to deconsolidation of subsidiary | |||||
| Proceeds from sale of intellectual property | |||||
| Net cash flows provided by (used in) investing activities | |||||
| Cash flows from financing activities | |||||
| Proceeds – issue of preferred stock - subsidiary | |||||
| Subsidiaries | |||||
| Total proceeds – issue of preferred stock - subsidiary | |||||
| Proceeds – issue of Senior Secured Convertible Note | |||||
| Proceeds from issuance of equity | |||||
| Proceeds – issue of common stock | |||||
| Subsidiaries | |||||
| At-The-Market Facility | |||||
| Total proceeds – issue of common stock | |||||
| Proceeds – majority-owned subsidiary common stock - Committed Equity Facility and At-The-Market Facility | |||||
| Proceeds – subsidiary common stock - Committed Equity Facility and At-The-Market Facility | |||||
| Payment – financing costs – debt exchange | |||||
| Payment – Senior Secured Convertible Note – acceleration floor payments | |||||
| Proceeds – issue common stock – Employee Stock Purchase Plan | |||||
| Subsidiaries | |||||
| Total proceeds – issue common stock – Employee Stock Purchase Plan | |||||
| Proceeds – majority-owned subsidiary common stock – Employee Stock Purchase Plan | |||||
| Proceeds – subsidiary common stock – Employee Stock Purchase Plan | |||||
| Proceeds – exercise of stock options issued under equity plan of subsidiary | |||||
| Subsidiaries | |||||
| Total proceeds – exercise of stock options issued under equity plan of subsidiary | |||||
| Net cash flows provided by financing activities | |||||
| Net increase (decrease) in cash | |||||
| Cash, beginning of period | |||||
| Cash, end of period | |||||
Loading...